List view / Grid view
Looking at disease through a patient’s memory B cells can reveal vulnerabilities within pathogens. In this article, Dr Purnanand Sarma, President and Chief Executive Officer of Immunome, explores how advancements in memory B-cell antibody-based treatments will improve our understanding of how these cells can aid in fighting cancer and other diseases.
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
Scientists have found that molecules produced by cells in response to stress may be indicators of various diseases.
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
A new study from the University of Michigan Rogel Cancer Center, US has revealed that a cytokine and a fatty acid can work together to trigger ferroptosis. Here, Dr Weiping Zou, the lead researcher from the study, outlines how this process could be used to target cancer cells and enhance immunotherapies.
Researchers have been using brain organoids to understand how a mutated gene affects the brain at its very early stage of development.
A new study by University of Texas Health Science Center at San Antonio has found that boosting liver mRNAs in obese mice reduces appetite and body weight.
Almirall and University of Dundee announce a collaboration to develop a novel treatment to fully control itch in skin diseases and achieve a prolonged and profound therapeutic effect for patients.
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
Read this bulletin to learn about a Bio-Rad study where they developed and tested a 16-parameter flow cytometry panel applicable to the interrogation of a range of biologically relevant markers of T cell activation.
By studying the gut microbes of rats, researchers discovered that a bacteria known as Coprococcus comes contributes to resistance to high blood pressure drugs.
New research could point towards a way to restore immune function in patients with immune disorders involving B cell signalling deficiencies.
Dr Roger Dmochowski, Professor of Urology and Associate Surgeon in Chief for Vanderbilt University Medical Center, discusses the promise of potential new regenerative for Stress Urinary Incontinence.
Researchers at the Weizmann Institute of Science have shown that fibroblasts may be a factor in the origin of scleroderma.
Researchers have discovered how immune system dendritic cells are key to maintaining and regulating response to immunotherapy.
